|

TNO155 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Novartis Pharmaceuticals1

Indications

  • Advanced Solid Tumors Harboring the KRAS G12C Mutation1
  • Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer1
  • Lung Cancer1
  • Cancer1

Other1 trial

Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.